Ex-Amazon Engineer Funds AI Drug Discovery
Alex Wiltschko, a former Amazon AI engineer, this week emerged from stealth with Rhizome Research and invested six figures of personal capital to build generative AI for small-molecule drug design. The startup says early prototypes generated candidates for cancer and neurodegenerative disorders, though clinical trials are pending. Rhizome aims to accelerate discovery and cut costs in drug development by predicting and proposing novel compounds.
Key Points
- 1Launches Rhizome Research with six-figure personal funding to generate small-molecule candidates
- 2Uses generative AI trained on molecular datasets to propose novel compounds, speeding discovery iterations
- 3Suggests tech-to-biotech talent shift could reduce timelines and costs for preclinical candidate selection
Scoring Rationale
Startup demonstrates promising AI-driven drug discovery, but limited evidence and early-stage status constrain immediate industry impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
